Sonar Launches SonarQube 9.9 LTS to Help Organizations Achieve a State of Clean Code
7.2.2023 14:00:00 EET | Business Wire | Press release
SonarSource, the leading provider of Clean Code solution, today launched SonarQube 9.9 Long-Term Support (LTS). The new release empowers organizations to achieve the Clean Code state quickly, securely, and at scale. With accelerated pull request analysis, support for building and deploying secure cloud-native applications, sophisticated enterprise-grade capabilities, and many innovations related to the detection engine and contextual education, SonarQube 9.9 LTS supercharges organizations to deliver new business value and keep their software a long-term asset.
“Sonar has greatly helped us benchmark and standardize the quality of our codebase - and the LTS makes it much easier for us to deliver Clean Code. The integration with Azure DevOps from a project-to-project perspective as well as the token lifecycle management will be greatly appreciated by our admins and will help streamline our process,” said Stefan Euripidou, Enterprise Architect for DevOps and CICD at Vodafone Group.
Clean Code is essential for every organization competing in today’s digital-driven economy. Poor quality software costs businesses over $2 trillion a year in the US alone, hampering service quality, brand reputation, worker productivity, and employee retention. Code is the difference between good and bad software. Sonar’s latest 9.9 LTS release introduces key capabilities to enable enterprises to build better software in a sustained manner.
“Our mission is to equip organizations with the solution and methodology to achieve a state of Clean Code, making all code fit for development and production. When companies embrace Clean Code practices, they can derive more from their software, minimize risks, and ensure that their software continues to stay valuable,” said Olivier Gaudin, Founder and CEO of SonarSource. “SonarQube 9.9 LTS was designed to not only provide immediate value to our users for their current development but to steadily drive organizations toward a state of Clean Code in a way that’s predictable, reliable, and sustainable.”
Key release innovations
Pull Request Analyzed in Minutes
SonarQube 9.9 LTS provides a significant speed boost for Pull Request (PR) analysis. PRs are now analyzed more than twice as fast, while still providing the same high-precision results. With the implementation of incremental analysis and server-side caching, analysis is more efficient. As developers write and commit code, Pull Request analysis is an important step in merging new code changes to the main branch. Faster analysis means a more efficient software development lifecycle, as developers spend less time waiting and more time delivering business critical features.
Secure Cloud Native Applications
As applications move to the cloud, organizations must ensure the security of not only the source code, but also their configuration files and deployments. SonarQube 9.9 LTS delivers in-depth analysis capabilities to detect ‘secrets’ in code, bad practices, and vulnerabilities so that developers can build and deploy secure cloud native applications. The release adds support for major cloud providers – AWS, Google Cloud, Microsoft Azure, and their underlying technologies – serverless and SAM frameworks, AWS Cloud Development Kit, Infrastructure-as-Code tools (Terraform and Cloudformation), and containerization tools with Kubernetes and Docker. With these additions, organizations can be sure that their cloud native apps are as secure as their traditional on-prem apps.
Enterprise-grade features for Coding at Scale
SonarQube 9.9 LTS introduces stronger access management, administration, governance, and reporting capabilities, enabling organizations to better manage the security and administration of their SonarQube instance and their portfolio of code assets. Chief among these new features are advanced security and compliance reporting, project and portfolio reporting, secure token handling, SCIM integration for user management, and more. Customers using the Data Center Edition can now deploy SonarQube clusters with Kubernetes. Together, these reporting, authentication and operational improvements make it easier to use, secure, and manage SonarQube instances than ever before.
“The latest SonarQube release introduces a variety of critical new features. Not only will we benefit from the new Terraform scan support, but we will also use the enhanced reporting and administration capabilities to strengthen our Quality Gates and streamline communication efforts,” said Vojtech Varga, Service Manager at Siemens AG. “Sonar’s LTS is an opportunity for us to access the latest fixes and features to ensure that we continue to operate with the highest-quality code.”
Increased Detection of all Issue Types; Rich Educational Guidance
Continued innovation in the detection engine allows for improved precision, speed, accuracy, and coverage of all issue types. Users can find and fix more issues in their code. And this LTS release brings in rich educational content to make taint analysis rules easy to understand and contextual to the users’ code and framework – continuing the advancement of the company’s education initiative.
Clean as You Code, the Sustainable Approach to Clean Code
Sonar is a strong proponent of deploying compliant quality gates that will progressively drive organizations to reach a state of Clean Code. This LTS release adds enhancements to the quality gate user experience to help everyone implement and practice Clean as You Code. Quality gates that are not compliant with this methodology can be easily identified and updated.
SonarQube 9.9 LTS is now available for everyone. Read more in the full release announcement and download the LTS for your edition here.
About SonarSource
Sonar empowers developers and organizations to systematically achieve a state of Clean Code so that all code is fit for development and production. By applying the Sonar Clean as You Code methodology, organizations minimize risk, reduce technical debt, and derive more value from their software in a predictable and sustainable way.
The open source and commercial Sonar solution – SonarLint, SonarCloud, and SonarQube – supports over 30 programming languages, frameworks, and infrastructure technologies. Trusted by more than 400,000 organizations globally to clean more than half a trillion lines of code, Sonar is integral to delivering better software.
To learn more about SonarSource, please visit https://www.sonarsource.com/company/about/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230207005514/en/
Contact information
Media Contact
Jordan Tewell
10Fold for SonarSource
415-666-6066
sonarsource@10fold.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
